FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366593997> ?p ?o ?g. }

• W4366593997 endingPage "e878" @default.
• W4366593997 startingPage "e878" @default.
• W4366593997 abstract "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired bone marrow disease characterized by intravascular hemolysis, thrombophilia, and bone marrow failure.1 Treatment options for PNH remained limited until the terminal complement inhibitor eculizumab became available. Eculizumab effectively reduces intravascular hemolysis in PNH, but in almost all patients on eculizumab complement C3d-opsonized PNH erythrocytes arise and become a target of phagocytosis by macrophages in liver and spleen resulting in a variable degree of extravascular hemolysis.2 Chronic intravascular hemolysis in untreated PNH patients leads to urinary iron loss from hemosiderinuria and often results in iron deficiency.1 In contrast, in transfusion-independent PNH patients treated with eculizumab, observed increases in ferritin levels have raised concerns about possible iron overload. The major regulator of iron homeostasis is the hepatic peptide hormone hepcidin. Hepcidin modulates the iron availability for erythropoiesis by controlling both iron absorption in the duodenum and recycling of iron by macrophages by 2 mechanisms: occlusion of the open-outward conformation of the cellular exporter ferroportin, and induction of endocytosis and degradation of ferroportin.3 Hepcidin is a negative regulator of iron absorption and mobilization. High levels inhibit both duodenal iron absorption and iron release from macrophages, whereas low levels promote iron absorption.3 Recently, the hormone erythroferrone (ERFE) was discovered as main erythroid regulator of hepcidin. ERFE is produced by erythroblasts and its production is induced by erythropoietin. ERFE suppresses the production of hepcidin to facilitate iron delivery during stress erythropoiesis but also contributes to iron overload in congenital anemias with ineffective erythropoiesis such as β-thalassemia and X-linked sideroblastic anemia.4 Hyperferritinemia during eculizumab therapy has been attributed to a decline of renal iron loss, as well as iron deposition in the reticuloendothelial system (RES) as a result of C3d-mediated extravascular hemolysis.5–7 However, the effect of eculizumab on iron metabolism has not been studied well, and the role hepcidin and ERFE play in the development of hyperferritinemia is unknown. The aim of this study was to investigate how eculizumab affects iron metabolism in PNH. Therefore, a single-center observational study was conducted in the Radboudumc Expertise Center for PNH in Nijmegen, The Netherlands, and included 13 transfusion-independent PNH patients not treated with a complement inhibitor and 23 transfusion-independent PNH patients who received at least 6 months of eculizumab (Suppl. Table S1). In these patients, we characterized the association between degree of hemolysis and iron parameters, including serum hepcidin and ERFE. A detailed description of material and methods is provided in the supplemental digital content. Individual patient data are depicted in Suppl. Table S2. First, serum ferritin levels were retrospectively collected from medical records of the transfusion-independent patients on eculizumab to study ferritin levels during the course of treatment (Suppl. Figure S1). Ferritin levels increased with time. Mean increase of serum ferritin per patient per year of therapy ranged from −28.7 μg/L to 213.5 μg/L (median = 48.9 μg/L). Second, serum ferritin levels and transferrin saturation (TSAT) were measured at a single time-point in all patients (Figure 1A). Note that the duration of eculizumab therapy differed per patient at the time iron parameters were measured. Ferritin levels were significantly higher in treated patients (median, 301 μg/L; range, 11–913 μg/L) than untreated patients (median, 103 μg/L; range, 25–290 μg/L; P = 0.006). In addition, ferritin levels above the upper limit of the reference range were observed in 13 out of 23 treated patients. In patients on eculizumab, ferritin levels significantly correlated with the duration of therapy (r = 0.495, P = 0.016). TSAT did not significantly differ between the groups (P = 0.921), and in 12 out of 13 untreated patients and 22 out of 23 treated patients, TSAT was below 45%.Figure 1.: Iron parameters, and correlations between markers for intravascular and extravascular hemolysis and iron parameters in transfusion-independent PNH patients not treated with a complement inhibitor and PNH patients treated with eculizumab. (A) Serum ferritin and TSAT determined in transfusion-independent PNH patients not treated with a complement inhibitor and transfusion-independent PNH patients treated with eculizumab. Boxes show median and first and third quartiles. Whiskers extend to minimum and maximum values. Dashed lines represents the upper limits of reference ranges. In the graph depicting serum ferritin levels, the lower dashed line represents the upper limit of the reference range of ferritin for premenopausal women and the upper dashed line represents the upper limit of the reference range of ferritin for men and postmenopausal women. Statistical significant differences between groups are highlighted with bars and corresponding P-values, Mann-Whitney U test. (B) Serum hepcidin, hepcidin/ferritin ratio, and ERFE determined in transfusion-independent PNH patients not treated with a complement inhibitor and transfusion-independent PNH patients treated with eculizumab. Boxes show median and first and third quartiles. Whiskers extend to minimum and maximum values. Upper limits of reference ranges of hepcidin and hepcidin/ferritin ratios are not depicted here as these are outside the axis limits. Reference ranges of serum hepcidin levels are <0.5–13.0 nM, <0.5–16.5 nM, and <0.5–15.5 nM for premenopausal women, postmenopausal women, and men, respectively. Reference ranges of hepcidin/ferritin ratios are 3.2–176.4 pmol/μg, 9.6–150.9 pmol/μg, and 3.1–92.7 pmol/μg for premenopausal women, postmenopausal women, and men, respectively.15 For ERFE, no reference intervals are available yet. Median level of ERFE determined in 10 healthy controls is 0.8 ng/mL (range, 0.2–27.5). Statistical significant differences between groups are highlighted with bars and corresponding P-values, Mann-Whitney U test. (C) Correlation between absolute reticulocyte count and hepcidin/ferritin, and absolute reticulocyte count and ERFE in transfusion-independent PNH patients not treated with a complement inhibitor and transfusion-independent PNH patients treated with eculizumab. Two ERFE outliers (1 in the untreated group [ERFE = 43.3 ng/mL] and 1 in the treated group [ERFE = 102.9 ng/mL]) were excluded from the analysis. Spearman correlation coefficients are depicted in each graph with corresponding P-values. P-values <0.05 are considered to be significant. PNH = paroxysmal nocturnal hemoglobinuria; ERFE = erythroferrone; TSAT = transferrin saturation.In both the groups, markers for intravascular hemolysis (lactate dehydrogenase [LDH] and absolute reticulocyte count [ARC]) and extravascular hemolysis (ARC and percentage of C3d-opsonized PNH erythrocytes7) were measured. In patients on eculizumab, intravascular hemolysis was adequately inhibited; however, a variable degree of C3d-mediated extravascular hemolysis occurred. In these patients, we found a significant correlation between mean ferritin increase per year, and both ARC (r = 0.737; P < 0.001; Suppl. Figure S2A) and C3d opsonization (r = 0.533; P = 0.011; Suppl. Figure S2B). Taken together, we showed that PNH patients on eculizumab indeed frequently develop hyperferritinemia. Moreover, we confirmed that the degree of C3d-mediated extravascular hemolysis is strongly associated with the development of iron accumulation in the RES in these patients, as evidenced by hyperferritinemia in the presence of normal TSAT.8–10 Subsequently, serum hepcidin and ERFE levels were determined (Figure 1B), and correlated with markers for hemolysis in both treated and untreated patients. Because there was a significant correlation between LDH and ARC in untreated patients (r = 0.587; P = 0.045; Suppl. Figure S3), and percentage of C3d-opsonized PNH erythrocytes and ARC in treated patients (r = 0.662; P = 0.001; Suppl. Figure S2C), for the rest of the analysis, ARC was used as marker for intravascular and extravascular hemolysis in untreated and treated PNH patients, respectively. Serum hepcidin levels were significantly higher in treated patients (median, 3.8 nM; range, 0.5–9.9 nM) compared with untreated patients (median, 1.0 nM; range, 0.5–7.9 nM; P = 0.001). To correct hepcidin levels for degree of body iron load, and thus to assess other modulators of hepcidin than body iron status, the hepcidin/ferritin ratio was calculated. There was no significant difference in hepcidin/ferritin ratios between the groups (P = 0.193). As reference intervals for ERFE are not available, serum of 10 healthy volunteers (Suppl. Table S3) was collected to compare ERFE levels of patients with those of healthy controls. Serum ERFE levels were significantly increased in both untreated (median, 8.3 ng/mL; range, 0.8–43.3 ng/mL) and treated patients (median, 8.9 ng/mL; range, 1.4–102.9 ng/mL) compared with healthy controls (median, 0.8 ng/mL; range, 0.2–27.5 ng/mL; P < 0.001 and P = 0.002, respectively) but did not significantly differ between the 2 patient groups (P = 0.610). In patients not treated with eculizumab, there was a significant correlation between ARC and both hepcidin/ferritin ratio (r = −0.670; P = 0.012) and ERFE (r = 0.587; P = 0.045; Figure 1C). Therefore, it is likely that untreated patients with intravascular hemolysis have suppressed hepcidin levels as a result of the combination of iron deficiency due to renal iron loss as well as increased ERFE production induced by enhanced erythropoiesis (Figure 2A). In line with Waheed et al,6 we postulated that hepcidin levels remain low relative to ferritin levels upon initiation of eculizumab because of continuous increased erythropoiesis with high iron demand in patients with ongoing C3d-mediated extravascular hemolysis. Indeed, ARC inversely correlated with hepcidin/ferritin ratio (r = −0.503; P = 0.017) and positively correlated with ERFE (r = 0.630; P = 0.002; Figure 1C). Based on these results, we hypothesize that in patients on eculizumab with ongoing extravascular hemolysis, both a decline of renal iron loss and erythropoiesis-mediated suppressed hepcidin levels contribute to a positive net iron balance and subsequent progressive iron deposition in the RES (Figure 2B).Figure 2.: Conceptual model of iron regulation in transfusion-independent untreated and eculizumab-treated patients with PNH. (A) Intravascular hemolysis in untreated PNH patients leads to supressed serum hepcidin levels as a result of iron deficiency due to urinary iron loss from hemosiderinuria as well as increased ERFE production induced by enhanced erythropoiesis. Low serum hepcidin levels promote duodenal absorption and iron release from macrophages of the RES in order to increase the iron availability for erythropoiesis. (B) Once intravascular hemolysis is blocked by the complement-C5 inhibitor eculizumab, urinary iron loss is inhibited. However, patients develop a variable degree of extravascular hemolysis, caused by phagocytosis of complement-C3d-opsonized PNH erythrocytes in the RES, leading to iron sequestration in macrophages. Because of a persistent enhanced erythropoiesis, ERFE production is increased, resulting in serum hepcidin levels that remain low relative to ferritin levels. The combination of both a decline of renal iron loss and erythropoiesis-mediated suppressed hepcidin levels contribute to a positive net iron balance and subsequent progressive iron deposition in the RES in patients on eculizumab with ongoing extravascular hemolysis. Figure created with BioRender.com. PNH = paroxysmal nocturnal hemoglobinuria; ERFE = erythroferrone; RES = reticuloendothelial system.The results of this study do not explain why TSAT remains low, which will limit parenchymal iron overload in hyperferritinemic PNH patients on eculizumab. This is in contrast to what is observed in patients with iron loading anemias due to an ineffective erythropoiesis, where hepcidin is suppressed as well (relative to body iron levels), but leads to severe hepatocyte iron overload.11 One possible explanation is that the degradation of C3d-opsonized erythrocytes takes place in the RES, where iron is directly sequestered in macrophages. Although hepcidin levels are relatively low compared with ferritin levels in patients with more prominent extravascular hemolysis, absolute hepcidin levels in patients on eculizumab are elevated compared with untreated patients and might be not low enough to allow sufficient active ferroportin-mediated cellular iron efflux to compensate for the higher RES influx of iron. An alternative explanation for stable nonincreasing TSATs might be that macrophage iron release is partially impaired independent from the hepcidin-ferroportin axis. Theurl et al12 showed in mice that during massive hemolysis, the Kupffer-cell population in the liver is overwhelmed and these cells die. To compensate, blood-derived monocytes fill the vacant niche in the liver and differentiate into Kupffer-cell like macrophages. Because blood-derived monocytes from PNH patients lack glycosylphosphatidylinositol (GPI)-anchors, these Kuppfer-cell like macrophages are deficient of GPI-anchored proteins. A study of de Domenico et al13 showed that a GPI-linked splice variant of ceruloplasmin might be important for cellular iron export by stabilizing ferroportin on the cell membrane. As GPI-anchor deficient PNH cells lack GPI-linked ceruloplasmin, it is conceivable that iron release from GPI-anchor deficient Kupffer-like cells is impaired, leading to iron deposition in these macrophages. Future research is warranted to study this hypothesis. In conclusion, based on the results of this observational study, we postulate that in transfusion-independent PNH patients on eculizumab, the combination of a decline of renal iron loss as well as the emergence of extravascular hemolysis leading to increased RES-iron influx and erythropoiesis-mediated suppressed hepcidin contribute to progressive iron deposition in the RES. Long-term follow-up of serum iron parameters and organ iron quantification by MRI during therapy with terminal complement inhibitors is warranted to assess whether iron loading of the RES will eventually result in redistribution with toxic parenchymal iron overload, or that iron accumulation in the RES finally reaches a plateau due to further increased hepcidin levels. Given the findings in transfusion-independent patients on eculizumab, physicians should be even more aware of the development of iron overload in transfusion-dependent patients. Future studies may investigate whether proximal complement inhibitors, which prevent C3d-mediated extravascular hemolysis, also prevent the development of RES-iron accumulation.14 AUTHOR CONTRIBUTIONS CS, SS, DS, and SL designed the study. CS, FP, EJ, and CL acquired the data, conducted experiments, and performed data analysis. CS, SS, JJ, NB, DS, and SL wrote the article. JJ, NB, DS, and SL supervised the study. DATA AVAILABILITY Relevant individual patient data that support the findings of this study are available in the supplementary digital content (Suppl. Table S2). Remaining data are available on request from the corresponding author. DISCLOSURES The authors have no conflicts of interest to disclose. SOURCES OF FUNDING The authors declare no sources of funding." @default.
• W4366593997 created "2023-04-23" @default.
• W4366593997 creator A5000782466 @default.
• W4366593997 creator A5007551307 @default.
• W4366593997 creator A5012416377 @default.
• W4366593997 creator A5020940867 @default.
• W4366593997 creator A5054098878 @default.
• W4366593997 creator A5066703022 @default.
• W4366593997 creator A5079686066 @default.
• W4366593997 creator A5086860007 @default.
• W4366593997 creator A5091608460 @default.
• W4366593997 date "2023-04-19" @default.
• W4366593997 modified "2023-10-01" @default.
• W4366593997 title "Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria" @default.
• W4366593997 cites W2002360964 @default.
• W4366593997 cites W2009869329 @default.
• W4366593997 cites W2035390231 @default.
• W4366593997 cites W2049416980 @default.
• W4366593997 cites W2081653014 @default.
• W4366593997 cites W2086284653 @default.
• W4366593997 cites W2105923433 @default.
• W4366593997 cites W2143089664 @default.
• W4366593997 cites W2493546904 @default.
• W4366593997 cites W2616618502 @default.
• W4366593997 cites W2782047492 @default.
• W4366593997 cites W2835234069 @default.
• W4366593997 cites W3155876171 @default.
• W4366593997 cites W3172506357 @default.
• W4366593997 cites W4254938795 @default.
• W4366593997 doi "https://doi.org/10.1097/hs9.0000000000000878" @default.
• W4366593997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37092027" @default.
• W4366593997 hasPublicationYear "2023" @default.
• W4366593997 type Work @default.
• W4366593997 citedByCount "0" @default.
• W4366593997 crossrefType "journal-article" @default.
• W4366593997 hasAuthorship W4366593997A5000782466 @default.
• W4366593997 hasAuthorship W4366593997A5007551307 @default.
• W4366593997 hasAuthorship W4366593997A5012416377 @default.
• W4366593997 hasAuthorship W4366593997A5020940867 @default.
• W4366593997 hasAuthorship W4366593997A5054098878 @default.
• W4366593997 hasAuthorship W4366593997A5066703022 @default.
• W4366593997 hasAuthorship W4366593997A5079686066 @default.
• W4366593997 hasAuthorship W4366593997A5086860007 @default.
• W4366593997 hasAuthorship W4366593997A5091608460 @default.
• W4366593997 hasBestOaLocation W43665939971 @default.
• W4366593997 hasConcept C111684460 @default.
• W4366593997 hasConcept C126322002 @default.
• W4366593997 hasConcept C159654299 @default.
• W4366593997 hasConcept C203014093 @default.
• W4366593997 hasConcept C2777346216 @default.
• W4366593997 hasConcept C2777991916 @default.
• W4366593997 hasConcept C2778248108 @default.
• W4366593997 hasConcept C2778639011 @default.
• W4366593997 hasConcept C71924100 @default.
• W4366593997 hasConceptScore W4366593997C111684460 @default.
• W4366593997 hasConceptScore W4366593997C126322002 @default.
• W4366593997 hasConceptScore W4366593997C159654299 @default.
• W4366593997 hasConceptScore W4366593997C203014093 @default.
• W4366593997 hasConceptScore W4366593997C2777346216 @default.
• W4366593997 hasConceptScore W4366593997C2777991916 @default.
• W4366593997 hasConceptScore W4366593997C2778248108 @default.
• W4366593997 hasConceptScore W4366593997C2778639011 @default.
• W4366593997 hasConceptScore W4366593997C71924100 @default.
• W4366593997 hasIssue "5" @default.
• W4366593997 hasLocation W43665939971 @default.
• W4366593997 hasLocation W43665939972 @default.
• W4366593997 hasLocation W43665939973 @default.
• W4366593997 hasLocation W43665939974 @default.
• W4366593997 hasLocation W43665939975 @default.
• W4366593997 hasOpenAccess W4366593997 @default.
• W4366593997 hasPrimaryLocation W43665939971 @default.
• W4366593997 hasRelatedWork W1600863849 @default.
• W4366593997 hasRelatedWork W2044079477 @default.
• W4366593997 hasRelatedWork W2093098007 @default.
• W4366593997 hasRelatedWork W2098778053 @default.
• W4366593997 hasRelatedWork W2100352422 @default.
• W4366593997 hasRelatedWork W2149245783 @default.
• W4366593997 hasRelatedWork W2330809941 @default.
• W4366593997 hasRelatedWork W2993389739 @default.
• W4366593997 hasRelatedWork W3136167138 @default.
• W4366593997 hasRelatedWork W2519139876 @default.
• W4366593997 hasVolume "7" @default.
• W4366593997 isParatext "false" @default.
• W4366593997 isRetracted "false" @default.
• W4366593997 workType "article" @default.